经皮穴位电刺激联合穴位贴敷预防口腔恶性肿瘤患者放射性口干的效果观察

注册号:

Registration number:

ITMCTR2200006467

最近更新日期:

Date of Last Refreshed on:

2022-08-13

注册时间:

Date of Registration:

2022-08-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

经皮穴位电刺激联合穴位贴敷预防口腔恶性肿瘤患者放射性口干的效果观察

Public title:

Effectiveness of Transcutanclus electrical acupoint stimulation combined with acupoint application on radiation-induced xerostomia in patients with oral cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经皮穴位电刺激联合穴位贴敷预防口腔恶性肿瘤患者放射性口干的效果:一项随机对照试验

Scientific title:

Effect of Transcutanclus electrical acupoint stimulation combined with acupoint application on Radiation-Induced Xerostomia Among Patients With oral cancer: A Randomized Clinical Trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200062601 ; ChiMCTR2200006467

申请注册联系人:

郭星铜

研究负责人:

侯黎莉

Applicant:

xingtong guo

Study leader:

lili hou

申请注册联系人电话:

Applicant telephone:

18828077359

研究负责人电话:

Study leader's telephone:

13816033620

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xingtong123456789@163.com

研究负责人电子邮件:

Study leader's E-mail:

Pisces_liz@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市黄浦区制造局路639号

研究负责人通讯地址:

上海市黄浦区制造局路639号

Applicant address:

No. 639, Manufacturing Bureau Road, Huangpu District, Shanghai, China

Study leader's address:

No. 639, Manufacturing Bureau Road, Huangpu District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine, Chengdu, China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

SH9H-2022-T73-2

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海交通大学医学院附属第九人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Ninth People's Hospital of Shanghai Jiaotong University School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/3/17 0:00:00

伦理委员会联系人:

甄红 刘墨池

Contact Name of the ethic committee:

Hong Zhen, Mochi Liu

伦理委员会联系地址:

上海市黄浦区制造局路639号

Contact Address of the ethic committee:

No. 639, Manufacturing Bureau Road, Huangpu District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学医学院附属第九人民医院

Primary sponsor:

Shanghai Ninth People's Hospital, Affiliated to Shanghai Jiaotong University, School of Medicine

研究实施负责(组长)单位地址:

上海市黄浦区制造局路639号

Primary sponsor's address:

No. 639, Manufacturing Bureau Road, Huangpu District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

china

Province:

shanghai

City:

单位(医院):

上海交通大学医学院附属第九人民医院

具体地址:

上海市黄浦区制造局路639号

Institution
hospital:

The nineth Affiliated Hospital of Shanghai Jiao Tong University

Address:

No. 639, Manufacturing Bureau Road, Huangpu District, Shanghai, China

经费或物资来源:

上海交通大学医学院护理学科建设人才培养计划项目

Source(s) of funding:

Project for the School of Medicine, Nursing Discipline, Construction Talent Training Program at Shanghai Jiao Tong University

研究疾病:

口腔恶性肿瘤

研究疾病代码:

Target disease:

Oral cancer

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

上市后药物

Post-marketing clinical trial

研究目的:

通过前瞻性随机对照试验,验证经皮穴位电刺激足三里、三阴交、合谷穴联合穴位贴敷对于预防和减轻口腔癌患者放疗后口干的临床可行性和有效性,为构建放疗所致口干的中西医结合综合防治策略提供安全、有效的临床依据。

Objectives of Study:

A prospective randomized controlled trial was conducted to verify the clinical feasibility and efficacy of transcutaneous electrical stimulation of ST36, SP6, and LI4 points combined with acupressure for preventing and alleviating xerostomia after radiotherapy in oral cancer patients, and to provide a safe and effective clinical basis for the construction of an integrated Chinese and Western medicine prevention and treatment strategy for xerostomia caused by radiotherapy.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.经病理证实为口腔恶性肿瘤并接受放疗,年龄>18岁,没有肿瘤复发; 2.Karnofsky(KPS)功能状态评分≥60分,预计生存6个月以上; 3.知情同意后愿意参加且获得伦理委员会批准,能进行正常交流(言语或书面)的患者。 4.患者计划调强放疗,有或没有同步化疗/诱导治疗;没有摘除腮腺或腮腺导管结扎,尽力限制双侧腮腺的剂量,一侧腮腺平均剂量低于20Gy或两侧平均剂量低于25Gy。

Inclusion criteria

1. Oral cancer with radiation and histological confirmation.Adult > 18 years of age, without tumor recurrence. 2. with an anticipated survival of more than six months and Karnofsky performance status ≥ 60. 3. Able to give informed consent and ethics committee approval. Patients communicate normally and (verbally or in writing). 4. Planned intensity-modulated radiation therapy (IMRT), with or without concurrent chemotherapy or induction treatment, no parotid duct ligation or excision, and best attempts to minimize the bilateral parotid. One parotid gland receives an average dosage of less than 20 Gy, while both parotid glands get an average dose of less than 25 Gy.

排除标准:

1.放疗前由其他疾病(如干燥综合征或其他已知口干的潜在系统性疾病)引起的口干症; 2.患者既往接受过头颈部放疗(包括涎瘘); 3.不愿加入本试验患者,或治疗期间采取本法以外的其他治疗方法者,不能坚持完成疗程者等; 4.有交流障碍以及精神疾病者,带有心脏起搏器者,有心脑血管疾病者,癫痫患者,妊娠妇女,下肢疾病无法选穴者及对穴位贴过敏者; 5.目前有使用的唾液替代药物,如果患者正在使用任何唾液替代品,则要求他们在收集唾液和问卷数据前至少24小时内不要使用该产品; 6.正在服用氨磷汀、胆碱能受体激动剂药物(如皮罗卡平、西维美林),或其他 已知会影响唾液的药物功能的药物;

Exclusion criteria:

1. History of xerostomia prior to head and neck radiation therapy, Sj?gren's disease, salivary fistula, or another underlying systemic illness is known to cause xerostomia. 2. Patients who do not want to participate in this experiment or those who receive therapy using a different approach and are unable to follow the prescribed course of treatment 3. History of communication disorders, psychiatric disorders, epilepsy, and cardiovascular disease. with a cardiac pacemaker. pregnant women. 4. lower extremity disorders that prevent the selection of acupuncture points and allergies to acupuncture point patches. 5. If a patient was using any salivary substitute, they were asked to refrain from using the product for at least 24 hours prior to saliva and questionnaire data collection. 6. currently taking amifostine, cholinergic agonist medications (pilocarpine, cevimeline), or other medications are known to affect salivary function.

研究实施时间:

Study execute time:

From 2022-02-01

To      2023-05-31

征募观察对象时间:

Recruiting time:

From 2022-08-13

To      2022-12-31

干预措施:

Interventions:

组别:

对照组

样本量:

60

Group:

control group

Sample size:

干预措施:

经皮穴位电刺激

干预措施代码:

Intervention:

transcutaneous electrical acupoint stimulation

Intervention code:

组别:

试验组

样本量:

60

Group:

Experimental group

Sample size:

干预措施:

经皮穴位电刺激组联合贴敷组

干预措施代码:

Intervention:

transcutaneous electrical acupoint stimulation Combined Application

Intervention code:

组别:

空白对照组

样本量:

60

Group:

Blank control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Routine Care

Intervention code:

样本总量 Total sample size : 180

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

shanghai

City:

单位(医院):

上海交通大学医学院附属第九人民医院

单位级别:

三甲

Institution/hospital:

The nineth Affiliated Hospital of Shanghai Jiao Tong University

Level of the institution:

First-class Hospital at Grade 3

测量指标:

Outcomes:

指标中文名:

唾液流量

指标类型:

次要指标

Outcome:

salivary flow rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

头颈肿瘤相关生活质量量表评估(QLQH&N35)

指标类型:

次要指标

Outcome:

QLQH&N35

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

口腔干燥(XQ)评分

指标类型:

主要指标

Outcome:

Xerostomia Questionnaire(XQ)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

副作用指标

Outcome:

adverse event

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

唾液腺

Sample Name:

saliva

Tissue:

salivary glands

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究应用SPSS 25.0软件生成随机数,预实验阶段由统计人员生成24个随机数,采用随机数字表法将受试者按1:1:1的比例随机分到三个组。将随机数字对应编码放于密闭信封内实现随机隐匿,受试者按照入组先后顺序随机抽取数字。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number table approach was used in this study to allocate people at random to three groups in the ratios of 1:1:1. Random numbers were created using SPSS 25.0 software, and 24 random numbers were generated by statisticians during the pre-experimental phase. In order to achieve random concealment,&

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

暂无

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集用病例记录表(Case Record Form, CRF),使用Excel进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data was gathered using a Case Record Form (CRF), and it was managed using Excel.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统